View in EDS

Optimization of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations.

Saved in:
Bibliographic Details
Title: Optimization of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations.
Authors: Thomson C; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Braybrooke E; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Colclough N; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Davies NL; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Floc'h N; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Greenwood R; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Guérot C; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Hargreaves D; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Johnstrom P; AstraZeneca Translational Centre, Personal Healthcare and Biomarkers, AstraZeneca R&D, Karolinska Institutet, Department of Clinical Neuroscience, Karolinska University Hospital, R5:U1, Stockholm SE-171 76, Sweden., Khurana P; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Kostomiris DH; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Li S; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China., Lister A; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Lorthioir O; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Martin S; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., McCoull W; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., McLean NJ; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., McWilliams L; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Orme JP; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Packer MJ; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Pearson S; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Swaih AM; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Tentarelli S; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Tucker MJ; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Ward RA; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Wilkinson S; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Winlow P; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom., Wood IL; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
Source: Journal of medicinal chemistry [J Med Chem] 2024 Sep 28. Date of Electronic Publication: 2024 Sep 28.
Publication Type: Journal Article
Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39340451
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Optimization of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Thomson+C%22">Thomson C</searchLink>; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Braybrooke+E%22">Braybrooke E</searchLink>; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Colclough+N%22">Colclough N</searchLink>; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Davies+NL%22">Davies NL</searchLink>; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Floc'h+N%22">Floc'h N</searchLink>; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Greenwood+R%22">Greenwood R</searchLink>; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Guérot+C%22">Guérot C</searchLink>; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Hargreaves+D%22">Hargreaves D</searchLink>; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Johnstrom+P%22">Johnstrom P</searchLink>; AstraZeneca Translational Centre, Personal Healthcare and Biomarkers, AstraZeneca R&D, Karolinska Institutet, Department of Clinical Neuroscience, Karolinska University Hospital, R5:U1, Stockholm SE-171 76, Sweden.<br /><searchLink fieldCode="AU" term="%22Khurana+P%22">Khurana P</searchLink>; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Kostomiris+DH%22">Kostomiris DH</searchLink>; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.<br /><searchLink fieldCode="AU" term="%22Li+S%22">Li S</searchLink>; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China.<br /><searchLink fieldCode="AU" term="%22Lister+A%22">Lister A</searchLink>; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Lorthioir+O%22">Lorthioir O</searchLink>; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Martin+S%22">Martin S</searchLink>; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22McCoull+W%22">McCoull W</searchLink>; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22McLean+NJ%22">McLean NJ</searchLink>; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22McWilliams+L%22">McWilliams L</searchLink>; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Orme+JP%22">Orme JP</searchLink>; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Packer+MJ%22">Packer MJ</searchLink>; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Pearson+S%22">Pearson S</searchLink>; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Swaih+AM%22">Swaih AM</searchLink>; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Tentarelli+S%22">Tentarelli S</searchLink>; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.<br /><searchLink fieldCode="AU" term="%22Tucker+MJ%22">Tucker MJ</searchLink>; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Ward+RA%22">Ward RA</searchLink>; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Wilkinson+S%22">Wilkinson S</searchLink>; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Winlow+P%22">Winlow P</searchLink>; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Wood+IL%22">Wood IL</searchLink>; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229716531%22">Journal of medicinal chemistry</searchLink> [J Med Chem] 2024 Sep 28. <i>Date of Electronic Publication: </i>2024 Sep 28.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Chemical+Society%22">American Chemical Society </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9716531 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1520-4804 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200222623%22">00222623 </searchLink><i>NLM ISO Abbreviation: </i>J Med Chem <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39340451
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1021/acs.jmedchem.4c01792
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Optimization of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Thomson C
      – PersonEntity:
          Name:
            NameFull: Braybrooke E
      – PersonEntity:
          Name:
            NameFull: Colclough N
      – PersonEntity:
          Name:
            NameFull: Davies NL
      – PersonEntity:
          Name:
            NameFull: Floc'h N
      – PersonEntity:
          Name:
            NameFull: Greenwood R
      – PersonEntity:
          Name:
            NameFull: Guérot C
      – PersonEntity:
          Name:
            NameFull: Hargreaves D
      – PersonEntity:
          Name:
            NameFull: Johnstrom P
      – PersonEntity:
          Name:
            NameFull: Khurana P
      – PersonEntity:
          Name:
            NameFull: Kostomiris DH
      – PersonEntity:
          Name:
            NameFull: Li S
      – PersonEntity:
          Name:
            NameFull: Lister A
      – PersonEntity:
          Name:
            NameFull: Lorthioir O
      – PersonEntity:
          Name:
            NameFull: Martin S
      – PersonEntity:
          Name:
            NameFull: McCoull W
      – PersonEntity:
          Name:
            NameFull: McLean NJ
      – PersonEntity:
          Name:
            NameFull: McWilliams L
      – PersonEntity:
          Name:
            NameFull: Orme JP
      – PersonEntity:
          Name:
            NameFull: Packer MJ
      – PersonEntity:
          Name:
            NameFull: Pearson S
      – PersonEntity:
          Name:
            NameFull: Swaih AM
      – PersonEntity:
          Name:
            NameFull: Tentarelli S
      – PersonEntity:
          Name:
            NameFull: Tucker MJ
      – PersonEntity:
          Name:
            NameFull: Ward RA
      – PersonEntity:
          Name:
            NameFull: Wilkinson S
      – PersonEntity:
          Name:
            NameFull: Winlow P
      – PersonEntity:
          Name:
            NameFull: Wood IL
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 28
              M: 09
              Text: 2024 Sep 28
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1520-4804
          Titles:
            – TitleFull: Journal of medicinal chemistry
              Type: main
ResultId 1